"Anthracyclines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
| Descriptor ID |
D018943
|
| MeSH Number(s) |
D02.455.426.559.847.562.050 D04.615.562.050 D09.408.051.059
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Anthracyclines".
Below are MeSH descriptors whose meaning is more specific than "Anthracyclines".
This graph shows the total number of publications written about "Anthracyclines" by people in this website by year, and whether "Anthracyclines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 4 | 5 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anthracyclines" by people in Profiles.
-
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform. Breast Cancer Res Treat. 2022 Nov; 196(1):57-66.
-
An Updated Review on Radiation Treatment Management in Thymus Cancers. Clin Lung Cancer. 2022 11; 23(7):561-570.
-
Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. Crit Rev Oncol Hematol. 2021 Jan; 157:103143.
-
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. Oncologist. 2020 03; 25(3):e589-e597.
-
Anthracycline Exposure and Subsequent Critical Illness: Getting to the Heart of the Problem. Pediatr Crit Care Med. 2019 07; 20(7):672-673.
-
Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. J Clin Oncol. 2019 08 10; 37(23):2072-2081.
-
Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019 06 11; 3(11):1714-1721.
-
Risk factors for chemotherapy-related cardiac toxicity. Curr Opin Cardiol. 2019 05; 34(3):283-288.
-
Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018 07 01; 29(7):1535-1540.
-
Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes. Elife. 2018 05 08; 7.